Researchers at the University of Central Florida have found that genetic mutations linked to inherited Alzheimer’s disease can disrupt communication between motor nerves and muscle cells—even in a laboratory model containing no brain or spinal cord. The findings, published in Alzheimer’s & Dementia in April 2026, add to evidence that some movement-related effects of familial Alzheimer’s may arise in the peripheral nervous system.
Research context: The peer-reviewed study was published on April 16, 2026. It is receiving renewed attention as scientists explore whether Alzheimer’s-related changes extend beyond the brain; it is not a newly published November 2026 paper.
A New Clue About Alzheimer’s Beyond the Brain
Alzheimer’s disease is best known for its progressive effects on memory, reasoning, language and other cognitive abilities. It is associated with changes in the brain, including the accumulation of amyloid-beta and tau proteins, and the gradual loss of healthy connections between nerve cells.
Yet clinicians and researchers have also observed physical changes in some people with Alzheimer’s, including reduced muscle strength, slower walking speed and difficulties with balance or coordination. Scientists have been investigating whether these changes are simply downstream consequences of brain deterioration or whether the disease can also affect the peripheral nervous system—the network of nerves outside the brain and spinal cord.
The UCF study provides laboratory evidence for the second possibility in certain inherited forms of the disease. The researchers found that motor neurons carrying familial Alzheimer’s mutations could form neuromuscular connections that did not function normally, even when the brain and spinal cord were not part of the experimental system.
The result does not mean Alzheimer’s begins in the muscles, nor does it show that every patient will develop movement problems. Instead, it suggests that disease-associated genetic changes may have effects on the body’s motor system that are not entirely dependent on damage occurring in the brain.
Read the University of Central Florida’s explanation of the research and the full peer-reviewed study in Alzheimer’s & Dementia.
How the Scientists Investigated the Disease
The research team, led by Professor James Hickman and Research Professor Xiufang “Nadine” Guo of UCF, worked with collaborators to develop a human-cell laboratory model of the neuromuscular junction. The work involved researchers from UCF, Hesperos and Michigan State University College of Human Medicine.
A neuromuscular junction is the specialised meeting point where a motor neuron sends a signal to a muscle fibre. That signal triggers muscle contraction, allowing a person to move. The connection is essential for activities ranging from walking and standing to lifting objects and controlling small movements of the hands.
To model this connection, the team used motor neurons derived from induced pluripotent stem cells—adult cells reprogrammed into a stem-cell-like state and then guided to develop into specific cell types. The motor neurons carried mutations associated with familial Alzheimer’s. The researchers paired them with healthy skeletal muscle cells in a two-chamber microphysiological system.
Crucially, the model did not include the brain or spinal cord. This allowed the scientists to examine whether the genetic mutations could disrupt the nerve-to-muscle circuit directly, rather than through signals originating in the central nervous system.
The researchers assessed the formation and function of the neuromuscular junctions using functional measurements, including how reliably nerve stimulation produced a muscle response and how well the connections maintained performance. This approach offered a way to study the biological function of the system, rather than relying only on the appearance of cells under a microscope.
Two Familial Alzheimer’s Mutations Were Examined
The study examined motor neurons carrying two mutations associated with familial Alzheimer’s disease: PSEN1 A246E and APP K595N/M596L, commonly known as the APP Swedish mutation.
Familial Alzheimer’s is an uncommon inherited form of the disease. Some cases are linked to disease-causing variants in genes such as APP, PSEN1 and PSEN2. These inherited forms can cause symptoms to appear earlier than the more common late-onset form, although the age of onset varies between families and mutations.
In the UCF model, neuromuscular junctions formed with motor neurons carrying the PSEN1 A246E mutation showed severe functional deficiencies. Connections involving the APP Swedish mutation showed moderate deficiencies. The researchers reported that the mutations affected the performance of the nerve-muscle system, despite the use of healthy skeletal muscle cells.
The results are important because they indicate that the mutations themselves can contribute to dysfunction in the peripheral motor system. They do not establish that the same degree of impairment occurs in every person with familial Alzheimer’s or in people with the more common late-onset form.
Why the Nerve-Muscle Connection Matters
Movement depends on a chain of communication. The brain and spinal cord help plan and coordinate movement, while motor neurons carry electrical signals to muscles. At the neuromuscular junction, chemical signalling—principally involving the neurotransmitter acetylcholine—transmits the message that causes a muscle fibre to contract.
If the junction does not transmit signals reliably, muscle responses can become less effective. Depending on the underlying condition, people may experience weakness, reduced endurance or impaired movement. The UCF findings provide a possible biological route through which certain Alzheimer’s-linked mutations could contribute to motor difficulties.
However, the study was a laboratory investigation, not a clinical trial. It did not prove that the mutations cause a particular walking pattern or level of weakness in patients. More research involving people with familial Alzheimer’s is needed to establish how closely the laboratory measurements correspond to real-world symptoms.
Could Changes in Walking or Muscle Strength Help With Earlier Detection?
One possible implication is that researchers may need to pay closer attention to physical function when studying the earliest stages of Alzheimer’s. Some clinical observations have linked early Alzheimer’s with reduced muscle strength and slower gait, prompting questions about whether motor-system changes can appear before obvious cognitive symptoms.
If future studies confirm that specific neuromuscular abnormalities are associated with particular Alzheimer’s mutations and occur early in the disease process, tests of walking speed, balance, muscle strength or nerve-muscle signalling could become useful additions to research assessments.
That possibility remains a research question, not a diagnostic recommendation. Walking difficulties, falls, poor balance and muscle weakness have many possible causes, including arthritis, stroke, Parkinson’s disease, peripheral neuropathy, medication effects and cardiovascular or other medical conditions. These symptoms alone cannot diagnose Alzheimer’s disease.
For broader background on Alzheimer’s symptoms, risk factors and diagnosis, readers can consult the Alzheimer’s Association’s information on the disease.
Existing Alzheimer’s Medicines Did Not Correct the Modelled Deficits
The researchers also examined whether two medicines commonly used in Alzheimer’s care—memantine and galantamine—could improve the performance of the affected neuromuscular junctions in their laboratory model.
The study reported no significant functional improvement in the affected systems from these treatments. The result suggests that medicines used to address aspects of Alzheimer’s cognitive symptoms may not necessarily correct the peripheral neuromuscular abnormalities observed in this model.
This finding should not be interpreted as evidence that memantine or galantamine are ineffective for their established clinical uses. The experiment tested their effects on a specific laboratory model of nerve-muscle dysfunction. It does, however, raise the possibility that future therapies aimed at motor symptoms may need to target biological pathways different from those addressed by existing cognitive treatments.
Human-on-a-Chip Technology Opens Another Research Route
The study also highlights the potential of microphysiological systems, sometimes described as “human-on-a-chip” technology. These platforms bring human cells together in controlled laboratory environments to reproduce selected functions of tissues or organs.
Unlike experiments that examine one cell type in isolation, a neuromuscular model allows researchers to observe how motor neurons and muscle cells interact. It can help scientists measure function, investigate disease mechanisms and test candidate treatments in a human-cell environment.
Such models are not miniature versions of an entire human body. They cannot reproduce every influence of the immune system, blood supply, hormones, ageing, brain activity or other organs. Their value lies in answering carefully defined questions about selected biological systems. Findings must still be validated through further laboratory work and clinical research.
What Scientists Need to Establish Next
The next stage will be to determine whether the neuromuscular abnormalities seen in the laboratory can be demonstrated in people who carry the same inherited mutations. Researchers will also need to establish when these changes occur, how they relate to memory and thinking symptoms, and whether they are reversible or preventable.
Another major question is whether similar abnormalities occur in the more common late-onset form of Alzheimer’s. The current study examined two familial Alzheimer’s mutations, so its findings cannot automatically be extended to all people living with the disease.
Further work could also explore whether therapies designed to protect motor neurons or stabilise neuromuscular junctions can improve function in the model. If promising results emerge, they would need to be followed by appropriate safety and efficacy studies before any treatment could be recommended to patients.
A Significant Finding, Not Yet a New Test or Cure
The UCF research adds an important piece to the scientific understanding of familial Alzheimer’s: some disease-associated mutations can disrupt nerve-to-muscle communication independently of the brain and spinal cord in a human-cell model.
It does not show that Alzheimer’s starts in the muscles, establish walking problems as a reliable early warning sign, or provide a new diagnostic test or cure. Those possibilities require much more evidence, particularly from studies involving patients.
Nevertheless, the work broadens the questions scientists are asking about Alzheimer’s. A fuller understanding of the disease may require researchers to investigate not only memory and cognition, but also the wider nervous system and the physical functions that allow people to remain mobile and independent.
Research Sources
- Original peer-reviewed study: “Evaluating the peripheral nervous system pathology of Alzheimer’s disease utilizing a functional human NMJ microphysiological system” — Alzheimer’s & Dementia, April 16, 2026.
- Journal publication and study highlights — Alzheimer’s Association / Wiley.
- Bibliographic record and abstract — PubMed.
- University of Central Florida: UCF Study Suggests Some Alzheimer’s Symptoms May Begin Outside the Brain.
- Alzheimer’s Association: What Is Alzheimer’s Disease?
- Pexels License — information on free use of the illustrative photographs.
Image note: The photographs in this article are illustrative stock images and do not depict the UCF research team, the actual laboratory experiment or people with Alzheimer’s disease.